ANDA 90284, held by InvaGen Pharmaceuticals. Alfuzosin Hydrochloride.
As of Nov 22, 2026, ANDA 90284 (Alfuzosin Hydrochloride), held by InvaGen Pharmaceuticals, was first approved by FDA on Jan 17, 2012, with 4 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 17, 2012 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Alfuzosin Hydrochloride10MG · tablet, extended release;oral | Alfuzosin Hydrochloride | Rx |
| Nov 12, 2025 | Supplement 11Labeling · Standard review | Approved | None posted |
| Nov 12, 2025 | Supplement 16Labeling · Standard review | Approved | None posted |
| Jan 13, 2015 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jan 13, 2015 | Supplement 5Labeling · Standard review | Approved | None posted |
| Jan 17, 2012 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters